(Reuters) - Medical device maker Stryker Corp is not in talks to buy rival Boston Scientific Corp, the company said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday, two days after a media report of a potential deal between the two surfaced.
Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60. They closed up 7.4 percent on Monday.
There has been rapid consolidation across the healthcare industry in recent years, but there has been a slower stream of larger deals in the medical device sector.
A potential deal between Stryker and Boston Scientific would create a combined company with a market value of more than $110 billion.
Wall Street analysts said any deal between the two companies would be transformational, but were skeptical about the rationale of the deal.
"Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition," Stryker said.
The Wall Street Journal had reported on Monday that Stryker had made a takeover approach to Boston Scientific.
"The filing from Stryker states that the company is not in discussions with Boston Scientific. It does not deny that prior discussions took place," Jason Benowitz, senior portfolio manager at Roosevelt Investment Group said.
"Putting together a deal for Boston Scientific that creates value for Stryker shareholders would be a challenging high-wire act."
Roosevelt Investment does not own shares in either of the companies.
(Reporting by Ankur Banerjee and Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
